GPOL launches The Glasgow Cancer Tests
The College’s Glasgow Precision Oncology Laboratory (GPOL) has developed a ground-breaking new cancer test for research and clinical trials that could ultimately change the way cancer medicine is delivered.
The Glasgow Cancer Tests are a suite of affordable solid tumour and blood cancer tests, developed specifically to enable patients to benefit from real-world Precision Medicine based cancer treatments.
The tests are designed to be used in routine healthcare, such as the NHS, and around the world, to enable doctors to offer the latest treatments and trials to cancer patients. They will also help scientists discover what makes cancer resistant to chemotherapy drugs, as well as provide data that will aid the development of new treatments.
Professor Andrew Biankin, Regius Professor of Surgery and Director of the Glasgow Precision Oncology Laboratory (GPOL), Institute of Cancer Sciences, said: “The Glasgow Cancer Tests were created so that ultimately every patient with cancer could have access to the latest treatments and clinical trials. Our GPOL team of inventors, including Dr Susie Cooke, Head of Medical Genomics, Dr Philip Beer, Head of Genomic Strategy and Dr David Chang, Reader & Consultant Pancreatic Surgeon, have dedicated the last five years of their lives to creating the Glasgow Cancer test."
“This test will enable patients around the world to access the best treatments for their cancer. I’m extremely proud of what the team have done and where this might take us for healthcare in the future.”
First published: 6 December 2019